asxl1 C-terminal truncation and SRSF2 mutation drive leukemogenesis via immune reprogramming
Acute myeloid leukemia (AML) carrying mutations pertinent to chromatin-modification and spliceosome represents an aggressive subtype with poor prognosis.Specifically, mutations of genes encoding additional sex combs-like 1 (ASXL1), a member of the polycomb protein family [1, 2], and serine/arginine-rich splicing factor 2 (SRSF2), a member of RNA splicing machinery [3,4], are frequently found in myeloid neoplasms [5][6][7].The cooccurrence of ASXL1 and SRSF2 P95H mutations leads to a significantly worse prognosis than having either mutation alone, indicating a synergistic effect in leukemogenesis [1].Mice engineered with the Asxl1 C-terminal truncation and the Srsf2 P95H mutation developed leukemia characterized by a myeloid-biased hematopoietic stem cell (HSC) pool and a malignant transcriptomic signature [1].These findings correlate mutation combinations to leukemia progression, but the mechanisms driving leukemogenesis remain unclear, hindering targeted therapy development.Herein, we developed a zebrafish model carrying both mutations to gain new insights into the mechanisms underpinning the pathogenic synergism between asxl1 and SRSF2 P95H .By crossing zebrafish with a C-terminal truncation mutation in asxl1 [8] (referred to as "A") with Tg(Runx1: SRSF2 P95H ) (referred to as "S") transgenic zebrafish, which expresses the SRSF2 P95H mutation under the Runx1 promoter in the HSPC population [9] (Supplementary Fig. 1), we have generated a double mutant zebrafish model (referred to as "SA").At the embryonic stage, SA embryos showed a significant increase in myeloid progenitors, as shown by pu.1 expression, which was higher than asxl1 deletion or transgenic SRSF2 P95H alone (Fig. 1A,E).At 9-12 months, these double mutants exhibited an expanded monocytic compartment in their kidney marrow (KM), compared with the single mutants, as indicated by increased fluoride-sensitive NSE expression (Fig. 1B,F).Additionally, they exhibited higher KM blast
Authors
- Yiyue Zhang (ORCID: https://orcid.org/0000-0002-9402-3523)
- Lingge Tu
- David Liew (ORCID: https://orcid.org/0000-0001-8451-8883)
- Chun-fung Sin
- Hong‐Lin Chan (ORCID: https://orcid.org/0000-0001-9675-2554)
- Xuan Sun (ORCID: https://orcid.org/0000-0002-3051-1720)
- Stephen Kwok‐Wing Tsui (ORCID: https://orcid.org/0000-0003-0686-4259)
- Lichuan Zheng
- Wenqing Zhang (ORCID: https://orcid.org/0000-0002-3636-7133)
- Fangfang He (ORCID: https://orcid.org/0000-0001-9535-2241)
- Alvin Chun Hang (ORCID: https://orcid.org/0000-0002-4800-2844)
- Xinyu Miao
- Anskar Y.H. Leung (ORCID: https://orcid.org/0000-0001-9975-8687)
Institutions
- Hong Kong Polytechnic University (HK)
- HSBC Holdings (GB)
- Queen Mary Hospital (CN)
- Hong Kong Science and Technology Parks Corporation (HK)
- Guangzhou First People's Hospital (CN)
- HKU-Pasteur Research Pole (HK)
- APT Electronics (China) (CN)
- University of Hong Kong (HK)
- South China University of Technology (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Leukemia
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1038/s41375-025-02790-5
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Innovation and Technology Commission
- Hong Kong Government
- Cornell Center for Materials Research
- Health and Medical Research Fund